Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma
Our findings suggest that the likelihood of diagnosis of MGMT promoter methylation may vary with time of biopsy in GBM. Furthermore, theoretical modeling predicts that efforts to deliver TMZ after the daily peak of MGMT activity, with exact time being dose-dependent, may significantly enhance its therapeutic efficacy.
Authors
- Olivia Walch (ORCID: https://orcid.org/0000-0002-7881-6910)
- Omar H. Butt (ORCID: https://orcid.org/0000-0003-2252-3673)
- Erik D. Herzog (ORCID: https://orcid.org/0000-0001-7209-5174)
- Albert H. Kim (ORCID: https://orcid.org/0000-0002-1751-8493)
- Maria F. Gonzalez-Aponte (ORCID: https://orcid.org/0000-0002-8139-312X)
- Tatiana Simon (ORCID: https://orcid.org/0000-0001-5686-8798)
- Joshua B. Rubin (ORCID: https://orcid.org/0000-0002-7395-1937)
- Marc D. Ruben (ORCID: https://orcid.org/0000-0002-7893-0238)
- William A. Leidig (ORCID: https://orcid.org/0009-0008-3127-3905)
- Yitong Huang (ORCID: https://orcid.org/0000-0002-5200-8077)
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- St. Louis Children's Hospital (US)
- Smith College (US)
- Washington University in St. Louis (US)
- University of Michigan (US)
- Michigan Medicine (US)
- Itasca Consultants (United States) (US)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1007/s11060-025-05242-3
- Citations
- 3
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.88
Funders
- National Science Foundation
- Alvin J. Siteman Cancer Center
- National Institutes of Health
- McDonnell Center for Systems Neuroscience
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke